Smith & Nephew plc (SN.L) – What Are Analysts Thinking About This Stock?

Shares of Smith & Nephew plc (LON:SN) have been assigned a consensus rating of “Hold” from the nine brokerages that are presently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is GBX 1,255.

SN has been the subject of several recent analyst reports. Berenberg Bank lowered their target price on shares of Smith & Nephew from GBX 1,300 to GBX 1,250 and set a “hold” rating for the company in a research note on Friday, August 14th. JPMorgan Chase & Co. cut their price target on shares of Smith & Nephew from GBX 1,438 to GBX 1,290 and set a “neutral” rating on the stock in a report on Thursday, August 6th. Shore Capital Group reaffirmed a “buy” rating and set a GBX 1,000 price target on shares of Smith & Nephew in a research report on Tuesday, July 21st. Royal Bank Of Canada decreased their price objective on Smith & Nephew from GBX 1,350 to GBX 1,250 and set a “sector perform” rating for the company in a report on Thursday, August 6th. Finally, Citigroup cut Smith & Nephew to a “buy” rating in a research report on Friday, July 10th.

Smith & Nephew Stock Up 6.5%

Shares of Smith & Nephew stock opened at GBX 1,190 on Thursday. The stock has a 50-day moving average price of GBX 1,053.81 and a 200 day moving average price of GBX 1,152.03. The company has a debt-to-equity ratio of 73.07, a quick ratio of 0.84 and a current ratio of 2.14. The stock has a market cap of £13.05 billion, a P/E ratio of 42.84, a P/E/G ratio of 0.46 and a beta of 0.69.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.